Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Exp Hematol. 2019 Jun 28;75:53–63.e11. doi: 10.1016/j.exphem.2019.06.473

Figure 3. Treatment of PBSCs with TSA enhanced the marrow-repopulating potential.

Figure 3.

(A) A scatter plot showing the levels of human CD45+ cell engraftment in the bone marrow (BM) of NSG mice 8 weeks after transplantation with CD34+ cells cultured with TSA or DMSO. (B) Limiting dilution analysis to compare the frequency of SRCs in the progeny from TSA-treated, control-treated culture conditions and those from fresh uncultured CD34+ cells. (C) Representative BM flow cytometric analysis of 8 weeks multilineage hematopoietic differentiation potential of engrafted human hematopoietic cells treated with TSA in NSG mice. (D) A scatter plot showing the levels of human CD45+ cell engraftment in the BM of NSG mice 18 weeks after transplantation with their progeny after culture with TSA or DMSO.